



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/467,413	12/17/1999	ALBERTO A. GABIZON	5325-0161.30	2363

7590 04/24/2003

JUDY M MOHR
DEHLINGER & ASSOCIATES
P O BOX 60850
PALO ALTO, CA 94306

[REDACTED] EXAMINER

KISHORE, GOLLAMUDI S

ART UNIT	PAPER NUMBER
1615	

DATE MAILED: 04/24/2003

17

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/467,413	Applicant(s) Gabizon
	Examiner Gollamudi Kishore	Art Unit 1615
<i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i>		
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>three</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.		
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).		
Status		
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>Mar 27, 2003</u>		
2a) <input type="checkbox"/> This action is FINAL. 2b) <input checked="" type="checkbox"/> This action is non-final.		
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.		
Disposition of Claims		
4) <input checked="" type="checkbox"/> Claim(s) <u>1-12</u> is/are pending in the application.		
4a) Of the above, claim(s) _____ is/are withdrawn from consideration.		
5) <input type="checkbox"/> Claim(s) _____ is/are allowed.		
6) <input checked="" type="checkbox"/> Claim(s) <u>1-12</u> is/are rejected.		
7) <input type="checkbox"/> Claim(s) _____ is/are objected to.		
8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.		
Application Papers		
9) <input type="checkbox"/> The specification is objected to by the Examiner.		
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are a) <input type="checkbox"/> accepted or b) <input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.		
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of: 1. <input type="checkbox"/> Certified copies of the priority documents have been received. 2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received.		
14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) <input type="checkbox"/> The translation of the foreign language provisional application has been received.		
15) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.		
Attachment(s)		
1) <input type="checkbox"/> Notice of References Cited (PTO-892)		
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)		
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____		
4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____		
5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)		
6) <input type="checkbox"/> Other: _____		

Art Unit: :1615

DETAILED ACTION

Petition 1.137 (b) and filing as an RCE dated 3-27-03 are acknowledged.

Claims included in the prosecution are 1-12.

Claim Rejections - 35 U.S.C. § 102

1. **The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:**

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. **Claims 1-2 are rejected under 35 U.S.C. 102(b) as being anticipated by Mislick et al (Bioconjugate Chemistry, 1995) of record.**

Mislick teaches the delivery of folate-polylysine-DNA complexes to carcinoma cell cultures (note the entire publication).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant argues that the examiner misread applicant's remarks; according to applicant, element 3 of the method claim is not taught by Mislick and the element 3 in the method claim according to applicant is " whereby said administering is effective to achieve accumulation of the therapeutic compound". It would appear that applicant is not contesting Mislick's teaching of element 2 in the method claim (see response on page 5).

The examiner disagrees that Mislick does not teach element 3 since as the title of Mislick's publication itself reflects, it is drawn to the transfection of DNA by using folate-polylysine

Art Unit: :1615

complexes. That means, the therapeutic agent, DNA gets inside the cells (accumulates).

Applicant's arguments therefore, are not found to be persuasive.

3. Claims 1-2 and 4-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Lee et al, (BBA, 1995) of record.

Lee discloses folate-PEG-DSPE liposomes which contain doxorubicin and administration of this composition to several carcinoma cell lines (note the abstract).

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant's arguments are similar to those for Mislick's reference and therefore, the same response is deemed applicable.

4. Claims 1-2 and 4-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Goren (1997) or Horowitz (1997) of record.

Both Goren and Horowitz teach the administration of folate-DSPE-liposomes containing doxorubicin to carcinoma cell lines (note the entire publications).

Applicant's arguments are similar to those put forward for the above rejections and therefore, the same reasoning is applicable.

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

5. Claims 1-3 are rejected under 35 U.S.C. 102(a) as being anticipated by Brasier (5,804,445).

Art Unit: :1615

Brasier discloses compositions containing a polypeptide therapeutic agent formulated with folate-conjugated bovine serum albumin (note the abstract, col. 2, lines 23-30 and claim 21).

Applicant's arguments are similar to those put forward for the above rejections and therefore, the same reasoning is applicable.

Claim Rejections - 35 U.S.C. § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. Claims 1-2 and 4-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lee et al (BBA) or Goren (1997) or Horowitz (1997) of record cited above.

Lee, Goren and Horowitz do not specifically teach in vivo administration of the composition for the treatment of neoplastic diseases. However, it would have been obvious to one of ordinary skill in the art to administer the composition in vivo, with a reasonable expectation of success, based on the in vitro studies of the prior art. Although Lee, Goren, and Horowitz do not teach other therapeutic agents, it is deemed obvious to one of ordinary skill in the art to use any therapeutic drug with the expectation of obtaining similar results.

Art Unit: :1615

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant argues that none of the references teach or suggest that the administration of a folate targeted drug conjugate would be effective to achieve accumulation of the drug in MDR cells. This argument is not found to be persuasive since these references are clearly suggestive of folate mediated targeting of the same claimed drugs and therefore, one of ordinary skill in the art would be motivated to extrapolate the studies to MDR cells with a reasonable expectation of success.

8. Claims 1-3 are rejected under 35 U.S.C. 103(a) as being unpatentable over

Mislick or Brasier cited above, in view of Lee et al (BBA) or Goren (1997) or Horowitz (1997) of record cited above individually or in combination.

Mislick, and Brasier teach nucleic acid as the active agent in the folate conjugates and not instant therapeutic agents. However, it would have been obvious to one of ordinary skill in the art to use any therapeutic agent since that depends on the nature of the disease. One of ordinary skill in the art would be motivated to use instant chemotherapeutic drugs since the references of Lee, Goren and Horowitz show the routine practice in the art of using these drugs.

Applicant's arguments have been fully considered, but are not found to be persuasive. Applicant once again argues that none of the references teach or suggest that the administration of a folate targeted drug conjugate would be effective to achieve accumulation of the drug in MDR cells. This argument is not found to be persuasive since

Art Unit: :1615

these references are clearly suggestive of folate mediated targeting of the anti-neoplastic drugs and therefore, one of ordinary skill in the art would be motivated to extrapolate the studies to in vivo situations where the cancer involves MDR cells, with a reasonable expectation of success.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *G.S. Kishore* whose telephone number is (703) 308-2440.

The examiner can normally be reached on Monday-Thursday from 6:30 A.M. to 4:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *T.K. Page*, can be reached on (703)308-2927. The fax phone number for this Group is (703)305-3592.


Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [thurman.page@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is

Art Unit: :1615

**more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette
of the Patent and Trademark on February 25, 1997 at 1195 OG 89.**

**Any inquiry of a general nature or relating to the status of this application should
be directed to the Group receptionist whose telephone number is (703)308-1235.**



Gollamudi S. Kishore, Ph. D

Primary Examiner

Group 1600

gsk

April 22, 2003